Overview
GM2 gangliosidosis encompasses Tay-Sachs and Sandhoff disease, characterized by a deficiency in hexosaminidase enzymes leading to progressive neurodegeneration and typically fatal outcomes by early childhood 1.Diagnosis
Elevated levels of GM2 ganglioside in tissues, particularly in brain and nerve cells 1.
Clinical symptoms include developmental regression, seizures, and organomegaly 1.
Enzymatic assays confirming reduced hexosaminidase activity in leukocytes or other tissues 1.Management
Currently, no definitive treatment exists; supportive care focuses on managing symptoms 1.
Gene therapy using adeno-associated virus (AAV) vectors expressing β-N-acetylhexosaminidase shows promise in preclinical models, significantly extending lifespan in treated animals 1.Special Populations
Pediatrics: Early intervention with emerging gene therapies may offer extended survival and quality of life improvements 1.
Comorbidities: Emergence of peripheral organ dysfunction in extended lifespan cases highlights the need for multidisciplinary care addressing both central and peripheral manifestations 1.Key Recommendations
Monitor and manage symptoms with supportive care tailored to individual patient needs (Evidence: Expert opinion 1).
Consider enrollment in clinical trials evaluating gene therapy approaches for GM2 gangliosidosis, particularly in pediatric patients (Evidence: Moderate 1).
Address emerging peripheral organ dysfunction in patients with extended survival due to potential gene therapy, requiring comprehensive multidisciplinary management (Evidence: Expert opinion 1).References
1 Johnson AK, McCurdy VJ, Gray-Edwards HL, Maguire AS, Cochran JN, Gross AL et al.. Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy. Annals of neurology 2023. link